Plasma components: properties, differences, and uses (Q33401173)

26 July 2017

title

Plasma components: properties, differences, and uses (English)

1 reference

26 July 2017

author name string

Richard John Benjamin

series ordinal

1

1 reference

26 July 2017

Lisa Swinton McLaughlin

series ordinal

2

1 reference

26 July 2017

publication date

1 May 2012

1 reference

26 July 2017

1 reference

26 July 2017

volume

52 Suppl 1

1 reference

26 July 2017

page(s)

9S-19S

1 reference

Clinical use of plasma and plasma fractions

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2012.03622.X

Transfusion-free techniques in pediatric live donor liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2012.03622.X

Effective reduction of transfusion-related acute lung injury risk with male-predominant plasma strategy in the American Red Cross (2006-2008).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2012.03622.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2012.03622.X

Properties of pathogen-inactivated plasma components

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2012.03622.X

Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2012.03622.X

Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2012.03622.X

Protein quality in Mirasol pathogen reduction technology-treated, apheresis-derived fresh-frozen plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2012.03622.X

Update on pathogen reduction technology for therapeutic plasma: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2012.03622.X

A comparison of methods of pathogen inactivation of FFP

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2012.03622.X

Solvent/detergent-treated plasma: composition, efficacy, and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2012.03622.X

Sources of variation in factor VIII, von Willebrand factor and fibrinogen measurements: implications for detecting deficiencies and increased plasma levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2012.03622.X

A randomized trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2012.03622.X

SD Plasma in TTP and coagulation factor deficiencies for which no concentrates are available

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2012.03622.X

Photodynamic virus inactivation of blood components

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2012.03622.X

Methylene blue-treated fresh-frozen plasma: what is its contribution to blood safety?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2012.03622.X

Clinical tolerance of methylene blue virus-inactivated plasma. A randomized crossover trial in 12 healthy human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2012.03622.X

Assessment of safety in neonates for transfusion of platelets and plasma prepared with amotosalen photochemical pathogen inactivation treatment by a 1-month intravenous toxicity study in neonatal rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2012.03622.X

An active hemovigilance program characterizing the safety profile of 7483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2012.03622.X

Photochemical inactivation of pathogens in platelets and plasma: five years of clinical use in routine and hemovigilance. Towards a change of paradigm in transfusion safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2012.03622.X

Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2012.03622.X

Protein stability of previously frozen plasma, riboflavin and UV light-treated, refrozen and stored for up to 2 years at -30 °C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2012.03622.X

Characterization of plasma protein activity in riboflavin and UV light-treated fresh frozen plasma during 2 years of storage at -30 degrees C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2012.03622.X

Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2012.03622.X

Journey in reverse: TTP from bedside to blood bank to bench

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2012.03622.X

Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2012.03622.X

Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? No answer yet.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2012.03622.X

Design of the prospective randomized study for the treatment of patients with thrombotic microangiopathy. PRODROMI Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2012.03622.X

Cryoprecipitate poor plasma does not improve early response in primary adult thrombotic thrombocytopenic purpura (TTP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2012.03622.X

Solvent/detergent fresh frozen plasma as primary treatment of acute thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2012.03622.X

Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2012.03622.X

Fatal fibrinolysis during orthotopic liver transplantation in patients receiving solvent/detergent-treated plasma (Octaplas).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2012.03622.X

Study of three patients with thrombotic thrombocytopenic purpura exchanged with solvent/detergent-treated plasma: is its decreased protein S activity clinically related to their development of deep venous thromboses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2012.03622.X

Transfusing methylene blue-photoinactivated plasma instead of FFP is associated with an increased demand for plasma and cryoprecipitate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2012.03622.X

Methylene blue-photoinactivated plasma vs. fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2012.03622.X

Methylene blue-photoinactivated plasma versus quarantine fresh frozen plasma in thrombotic thrombocytopenic purpura: a multicentric, prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2012.03622.X

ADAMTS-13 activity and von Willebrand factor levels in methylene-blue photo-inactivated plasma processed by either the Springe method or an 'in house' system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2012.03622.X

Anaphylactic reaction after methylene blue-treated plasma transfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2012.03622.X

Anaphylactic shock to fresh‐frozen plasma inactivated with methylene blue

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2012.03622.X

Ambient overnight hold of whole blood prior to the manufacture of blood components

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1537-2995.2012.03622.X

10.1111/J.1537-2995.2012.03622.X

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference